Press Release

Category Added in a WPeMatico Campaign

Business Wire2 weeks ago

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

Findings from the Phase 3 study were presented at the 67th American Society of Hematology Annual Meeting and Exposition and…
Read More »
Cision PR Newswire2 weeks ago
0

MENU – ORDER AI Announces Global Expansion with New Multilingual Capabilities, Supporting WHO Guidance on Dietary Needs for GLP-1 Users

New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance of protein-focused nutrition. BOSTON, Dec.…
Read More »
Business Wire2 weeks ago

Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting

VGA039 is a once monthly, subcutaneously self-administered therapy for the treatment of bleeding disorders, starting with von Willebrand disease (VWD)…
Read More »
Cision PR Newswire2 weeks ago
0

Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC

LEXINGTON, Mass., Dec. 6, 2025 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company, announced new data from…
Read More »
Cision PR Newswire2 weeks ago
0

Best HR and Payroll Software (2025): QuickBooks Awarded for Accuracy and Team Management by Better Business Advice

NEW YORK , Dec. 6, 2025 /PRNewswire/ — Better Business Advice has recognized QuickBooks as the Best HR and Payroll Software…
Read More »
Business Wire2 weeks ago

Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

– Initial Results from Kite-753, Optimized with Novel Manufacturing Process That Preserves T-Cell Fitness, Show High Complete Response Rate and…
Read More »
Cision PR Newswire2 weeks ago
0

Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting

New long-term data presented at AES 2025 indicate reductions in seizure frequency are maintained for up to two years after treatment…
Read More »
Cision PR Newswire2 weeks ago
0

Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin’s Lymphoma at the 2025 ASH Annual Meeting

SHANGHAI, Dec. 6, 2025 /PRNewswire/ — Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology…
Read More »
Business Wire2 weeks ago

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of…
Read More »
Business Wire2 weeks ago

Orca Bio Presents New Clinical Data on Orca-T® in Older Patients Using Reduced Intensity Conditioning Plus New Analyses from the Precision-T Phase 3 Study at the 67th ASH Annual Meeting

Patients aged 60-75 treated with Orca-T and a reduced intensity conditioning regimen (RIC) experienced low incidence of acute and chronic…
Read More »

Previous page Next page